119 related articles for article (PubMed ID: 22032759)
1. The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.
Gallagher JC; Strzinek RA; Cheng RF; Ausmanas MK; Astl D; Seljan P
J Womens Health (Larchmt); 2012 Feb; 21(2):188-98. PubMed ID: 22032759
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff L; Gass M; Constantine G; Olivier S;
Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
[TBL] [Abstract][Full Text] [Related]
4. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d.
Khan A; Musgnung J; Ramey T; Messig M; Buckley G; Ninan PT
J Clin Psychopharmacol; 2014 Jun; 34(3):365-8. PubMed ID: 24717247
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
Archer DF; Seidman L; Constantine GD; Pickar JH; Olivier S
Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
[TBL] [Abstract][Full Text] [Related]
6. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
Archer DF; Dupont CM; Constantine GD; Pickar JH; Olivier S;
Am J Obstet Gynecol; 2009 Mar; 200(3):238.e1-238.e10. PubMed ID: 19167693
[TBL] [Abstract][Full Text] [Related]
7. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms.
Cheng RJ; Dupont C; Archer DF; Bao W; Racketa J; Constantine G; Pickar JH
Climacteric; 2013 Feb; 16(1):17-27. PubMed ID: 22646219
[TBL] [Abstract][Full Text] [Related]
8. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
9. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
Pinkerton JV; Constantine G; Hwang E; Cheng RF;
Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial.
Pinkerton JV; Archer DF; Guico-Pabia CJ; Hwang E; Cheng RF
Menopause; 2013 Jan; 20(1):38-46. PubMed ID: 23266839
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.
Montgomery SA; Fava M; Padmanabhan SK; Guico-Pabia CJ; Tourian KA
Int Clin Psychopharmacol; 2009 Nov; 24(6):296-305. PubMed ID: 19779354
[TBL] [Abstract][Full Text] [Related]
12. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
[TBL] [Abstract][Full Text] [Related]
14. Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder.
Ninan PT; Musgnung J; Messig M; Buckley G; Guico-Pabia CJ; Ramey TS
Prim Care Companion CNS Disord; 2015; 17(1):. PubMed ID: 26137358
[TBL] [Abstract][Full Text] [Related]
15. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder.
Tourian K; Wang Y; Ii Y
Int Clin Psychopharmacol; 2013 Jul; 28(4):206-13. PubMed ID: 23587982
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause.
Archer DF; Pinkerton JV; Guico-Pabia CJ; Hwang E; Cheng RF;
Menopause; 2013 Jan; 20(1):47-56. PubMed ID: 23266840
[TBL] [Abstract][Full Text] [Related]
17. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
[TBL] [Abstract][Full Text] [Related]
18. Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies.
Berhan Y; Berhan A
Ethiop J Health Sci; 2014 Jul; 24(3):209-18. PubMed ID: 25183927
[TBL] [Abstract][Full Text] [Related]
19. Identifying meaningful differences in vasomotor symptoms among menopausal women.
Wyrwich KW; Spratt DI; Gass M; Yu H; Bobula JD
Menopause; 2008; 15(4 Pt 1):698-705. PubMed ID: 18369313
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials.
Sun Z; Hao Y; Zhang M
Gynecol Obstet Invest; 2013; 75(4):255-62. PubMed ID: 23548358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
